Supported by LivaNova, the achievement expands the range of advanced neurological treatments available at the Level Six referral hospital in Kisumu.
The partners are now strengthening the programme to increase access to complex neurosurgical procedures while building local capacity to provide specialist care.
The expanded role is expected to strengthen referral services across Western Kenya and the wider East African region while reducing pressure on national referral hospitals.
Arprim Consultants presented a master plan and feasibility study led by Principal Architect Jared Momanyi, which sets out a phased approach to meet rising regional healthcare needs.
The new technology can complete blood screening within 20 to 35 minutes using advanced antigen-antibody detection methods, enabling clinicians to access safe blood more quickly for emergency and routine transfusions.
The hospital introduced the programme as part of broader efforts to reduce the burden of airborne diseases through stronger community engagement and evidence-based interventions.
The procedure, known as intraoperative pathological assessment using imprint cytology, enables pathologists to identify cancer cells within minutes.
The study found that resistance to commonly prescribed antibiotics, including ampicillin and cotrimoxazole, now exceeds 90% in some wound infection cases.
Using the new setup, clinicians can treat multiple oral conditions during one theatre session under general anaesthesia.
In sub-Saharan Africa, untreated jaundice-related complications responsible for up to 80 percent of neonatal deaths.